ClinicalTrials.gg
CompletedNCT00988208MainsailUpdated Apr 4, 2018Results posted

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

A Phase 3 interventional study of Lenalidomide and Docetaxel in Prostate Cancer, sponsored by Celgene. Completed at 210 sites in 21 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,059
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing lenalidomide in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Lenalidomide · Prostatic Neoplasms.

Enrollment
Largest of 10
1,059 · median 37
Started
2009
with 2 others
Phase 3
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
1 of 10
Celgene

Among the 10 studies testing lenalidomide in Prostatic Neoplasms, this one has the largest enrollment, is one of 3 that started in 2009, is the only one in phase 3, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 10 studies testing lenalidomide in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing lenalidomide in Prostatic Neoplasms as a file.
02

Study summary

The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.

The addition of lenalidomide to docetaxel and prednisone is proposed to increase the life expectancy of these subjects.

Read the detailed description

In November 2011, the Data Monitoring Committee concluded it was unlikely that the study would meet its primary endpoint of overall survival (OS) and recommended that the study be stopped. The study was terminated in accordance with this recommendation. All sites were instructed to immediately discontinue all patients from experimental lenalidomide/placebo treatment administered either in combination with chemotherapy or as a single agent following chemotherapy discontinuation. Subsequently, Protocol Amendment 3 was issued to provide for the following:

To continue to collect information on Second Primary Malignancies (SPMs) and additional treatments for Prostate Cancer in all randomized subjects during survival follow-up.

To continue to provide docetaxel and prednisone for up to 10 cycles to subjects randomized at non-US sites who were ongoing in the CC-5013-PC-002 protocol when the decision was made to discontinue lenalidomide/placebo and who were experiencing benefit as per investigator discretion. For subjects who had exceeded 10 cycles of docetaxel and prednisone at the time of Protocol Amendment 3 approval, an additional two cycles were provided.

All references to dosing and study procedures pertaining to the safety, efficacy, and exploratory endpoints of lenalidomide/placebo were discontinued as part of Protocol Amendment 3.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Castrate-Resistant Prostate Cancer
  • Revlimid
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must sign an Form (ICF)
  2. Males ≥ 18 years of age
  3. Able to adhere to the study visit schedule and requirements of the protocol
  4. (ECOG) performance status of ≤ 2
  5. of ≥ 12 weeks
  6. Willingness to participate in Patient-Reported Outcomes assessments
  7. Serum testosterone levels \< 50 ng/dL
  8. Confirmed adenocarcinoma of the prostate that is unresponsive or to hormonal therapy
  9. Have documented disease progression while receiving or following hormonal therapy as determined by increasing Serum Prostate Specific Antigen (PSA) level, Radiological Progression, or ≥2 new bone lesions
  10. Subjects must agree to receive counseling related to pregnancy precautions, teratogenic and other risks of lenalidomide
  11. Refrain from donating blood or semen as defined by protocol

Exclusion criteria

Exclusion Criteria:

  1. A history of disease that places subject at an unacceptable risk for study entry
  2. Prior Therapy with thalidomide, lenalidomide or pomalidomide
  3. Prior chemotherapy for prostate cancer
  4. Use of any other experimental drug or therapy within 28 days prior to randomization
  5. Prior radiation to ≥ 30% of bone marrow or any radiation therapy within 28 days prior to randomization
  6. Prior use of Strontium-89 at any time or Samarium-153 within 56 days prior to randomization
  7. Surgery within 28 days prior to randomization
  8. Concurrent anti-androgen therapy
  9. Abnormal serum chemistry or hematology laboratory values
  10. Significant active cardiac disease within the previous 6 months:
  11. Thrombotic or thromboembolic events within the past 6 months:
  12. History of peripheral neuropathy of ≥grade 2
  13. History of severe reaction to drugs formulated with polysorbate 80
  14. Paraplegia
  15. History of Central nervous system (CNS) or
  16. History of other than prostate cancer within the past 5 years, with the exception of treated basal cell/squamous cell carcinoma of the skin
  17. Concurrent use of alternative cancer therapies
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,059 participants (actual)

Study arms

  • Experimental
    Docetaxel, Prednisone, Lenalidomide (DPL)

    25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle

    Drug: Lenalidomide · Drug: Docetaxel · Drug: Prednisone

  • Experimental
    Docetaxel and Prednisone (DP)

    Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle

    Drug: Docetaxel · Drug: Prednisone · Drug: Placebo

Interventions

  • 25 mg lenalidomide orally once each day on Days 1-14

    Also known as: CC-5013, Revlimid

  • 75 mg/m2 intravenous docetaxel on Day 1

    Also known as: Taxotere

  • 5 mg prednisone orally twice daily on each day of the treatment cycle

    Also known as: There are multiple brand names for prednisone.

  • DrugPlacebo

    Oral placebo once each day on Days 1-14 of the treatment cycle

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley.

    Time frame: From randomization until death from any cause up to the cut-off date of 13 January 2012; up to approximately 26 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan

    Time frame: From randomization until disease progression or death from any cause; up to the cut-off date of 13 Jan 2012; maximum time on study was approximately 26 months

  2. Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria

    Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to \<10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size \<10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones

    Time frame: From day 1 to data cut-off 13 January 2012; maximum time on study was approximately 26 months

  3. Number of Participants With Treatment Emergent Adverse Events (AEs)

    A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

    Time frame: From the time from of first dose of study drug administration to 28 days after the last dose of study drug and up to the data cut off date of 13 January 2012; the maximum duration of study drug was 93 weeks for DP and 90.6 weeks for DPL

  4. Percentage of Participants Who Received Post-Study Therapies

    Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer.

    Time frame: The date when the first consent form was signed to the last date of AE data collection;up to 5 years; up to the date of the final data analysis date of 20 April 2017

  5. Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial

    Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial.

    Time frame: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days

  6. Time to Onset of Secondary Primary Malignancies

    Time of Onset of Secondary Primary Malignancies was considered an event of interest

    Time frame: The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days

07

Results

Posted Sep 5, 2013
Limitations and caveats
The independent DMC concluded that it was unlikely the trial would achieve its primary endpoint of improved overall survival. The sponsor agreed and the experimental lenalidomide/placebo treatment arm of the study was discontinued.

Participant flow

Following a safety and efficacy data review by the Data Monitoring Committee( DMC), the trial was stopped for futility. At that time, 1059 participants had been randomized and 1046 treated with either lenalidomide plus docetaxel and prednisone or placebo plus docetaxel and prednisone. A data cutoff date of 13 January 2012 was established.

Participant flow — Overall Study
MilestoneDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Started526533
Treated521525
Completed9595
Not completed431438
Withdrew: Adverse event71122
Withdrew: Disease progression10389
Withdrew: Withdrawal by subject5057
Withdrew: Death915
Withdrew: Lost to follow-up23
Withdrew: Protocol violation92
Withdrew: Sponsor decision10278
Withdrew: Clinical progression1716
Withdrew: Biochemical progression217
Withdrew: Clinical deterioration714
Withdrew: Subject decision/investigator discretion3232
Withdrew: Other83

Outcome measures

PrimaryOverall Survival (OS)

Overall survival (OS) was the time from the date of randomization to the date of death from any cause. If no death was reported for a participant before the cut-off date for OS analysis, OS was censored at the last date at which the participant was alive. The median OS was calculated based on Kaplan-Meier estimates and corresponding 95% confidence interval (CI) was calculated using the method provided by Brookmeyer and Crowley.

Time frame:
From randomization until death from any cause up to the cut-off date of 13 January 2012; up to approximately 26 months
Reported as:
Median · weeks
Overall Survival (OS)
weeksDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Overall Survival (OS)NA (75.71 to NA)77 (64.29 to 81.71)
Statistical analysis
  • Docetaxel/Prednisone/Placebo (DP) vs Docetaxel/Prednisone/Lenalidomide (DPL) · Log Rank · p = 0.0017 (p-value is based on unstratified log-rank test) · Hazard ratio (hr): 1.53 · 95% CI 1.17 to 2.00
SecondaryProgression-Free Survival (PFS)

PFS was the time from randomization to disease progression, or death, whatever occurred first. Progression criteria was met by analysis of target and non-target lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters while on study or the appearance of one or more new lesions; an increase of at least 5mm as a total sum. Lymph nodes identified as target lesions (≥ 15 mm diameter in short axis) will be followed and reported by changes in diameter of short axis; or the unequivocal progression of a non-target lesion defined as an increase in the overall disease burden based on the change in non-measurable disease that is comparable in scope to the increase required to declare PD for measurable disease; Two or more new bone lesions as detected by bone scan

Time frame:
From randomization until disease progression or death from any cause; up to the cut-off date of 13 Jan 2012; maximum time on study was approximately 26 months
Reported as:
Median · Weeks
Progression-Free Survival (PFS)
WeeksDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Progression-Free Survival (PFS)46 (42.14 to 53.57)45 (38.0 to 46.14)
Statistical analysis
  • Docetaxel/Prednisone/Placebo (DP) vs Docetaxel/Prednisone/Lenalidomide (DPL) · Log Rank · p = 0.0187 · Hazard ratio (hr): 1.32 · 95% CI 1.05 to 1.66P-value is based on unstratified log-rank test
SecondaryPercentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria

Objective response (OR) is defined as having complete response (CR) or partial response (PR) as best overall response based on RECIST Criteria 1.1 and defines a CR = Disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to \<10mm; PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; Progressed Disease (PD) = 20% increase in sum of diameters of target lesions taking as a reference the smallest sum of diameters and an absolute increase of ≥5 mm; the appearance of ≥1 new lesions; Stable Disease (SD)= Neither shrinkage to qualify for PR nor increase to qualify for PD taking the smallest sum diameters on study as reference. For non-target lesions a CR = Disappearance of all non-target lesions and all LN must be non-pathological in size \<10 mm; Non-CR/Non PD: persistence of one or more non-target lesions; PD = unequivocal progression of existing non-target lesions or appearance of new ones

Time frame:
From day 1 to data cut-off 13 January 2012; maximum time on study was approximately 26 months
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria
percentage of participantsDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Percentage of Participants With an Objective Response According to Response Evaluation Criteria in Solid Tumors - RECIST Version 1.1 Criteria24.322.1
Statistical analysis
  • Docetaxel/Prednisone/Placebo (DP) vs Docetaxel/Prednisone/Lenalidomide (DPL) · Chi-squared · p = 0.3975 · Odds ratio (or): 0.884 · 95% CI 0.665 to 1.176
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5-Fatal;

Time frame:
From the time from of first dose of study drug administration to 28 days after the last dose of study drug and up to the data cut off date of 13 January 2012; the maximum duration of study drug was 93 weeks for DP and 90.6 weeks for DPL
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participantsDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Any TEAE512517
Any TEAE related to lenalidomide or placebo379412
Any TEAE related to docetaxel/prednisone475481
Any severity grade 3-4 TEAE303381
Any serious AE (SAE)171279
Any SAE related to lenalidomide or placebo62167
Any SAE related to docetaxel/prednisone86182
Any AE causing discontinuation of lenalidomide/PBO82150
Any AE causing withdrawal of docetaxel/prednisone127169
Any TEAE leading to death1624
SecondaryPercentage of Participants Who Received Post-Study Therapies

Percentage of Participants Who Received Post-Study Therapies for advanced Prostate Cancer.

Time frame:
The date when the first consent form was signed to the last date of AE data collection;up to 5 years; up to the date of the final data analysis date of 20 April 2017
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Received Post-Study Therapies
Percentage of ParticipantsDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Percentage of Participants Who Received Post-Study Therapies70.869.0
SecondaryPercentage of Participants With Secondary Primary Malignancies During the Course of the Trial

Second primary malignancies were monitored as events of interest and reported as serious adverse events throughout the course of the trial.

Time frame:
The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
Reported as:
Number · percentage of participants
Percentage of Participants With Secondary Primary Malignancies During the Course of the Trial
percentage of participantsDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Invasive Secondary Primary Malignancies1.31.7
Non-invasive Secondary Primary Malignancies0.41.0
SecondaryTime to Onset of Secondary Primary Malignancies

Time of Onset of Secondary Primary Malignancies was considered an event of interest

Time frame:
The date when the first consent form was signed to the last date of AE data collection; up to the date of the final data analysis date of 30 November 2016; 7 years and 19 days
Reported as:
Median · months
Time to Onset of Secondary Primary Malignancies
monthsDocetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)
Time to Onset of Secondary Primary Malignancies29.7 (0.6 to 48.7)19.7 (3.7 to 65.0)

Adverse events

Collected over From first dose of study treatment to 28 days after the last dose; as of the final analysis cut-off of 20 April 2017; median overall duration of treatment was 22.1 months for DPL and 27.0 months for the DP group. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel/Prednisone/Lenalidomide (DPL)—283/525 (53.9%)513/525 (97.7%)
Docetaxel/ Prednisone/and Placebo (DP)—176/521 (33.8%)511/521 (98.1%)
Most frequent serious events
Showing 10 of 290
Most frequent serious events
EventDocetaxel/Prednisone/Lenalidomide (DPL)Docetaxel/ Prednisone/and Placebo (DP)
FEBRILE NEUTROPENIABlood and lymphatic system disorders52/52523/521
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders34/5258/521
NEUTROPENIABlood and lymphatic system disorders32/52511/521
PNEUMONIAInfections and infestations24/5258/521
DIARRHOEAGastrointestinal disorders22/5255/521
PYREXIAGeneral disorders19/5256/521
ANAEMIABlood and lymphatic system disorders18/52512/521
NEUTROPENIC SEPSISInfections and infestations15/5256/521
ATRIAL FIBRILLATIONCardiac disorders14/5258/521
DEHYDRATIONMetabolism and nutrition disorders13/5254/521
Most frequent other events
Showing 10 of 52
Most frequent other events
EventDocetaxel/Prednisone/Lenalidomide (DPL)Docetaxel/ Prednisone/and Placebo (DP)
FATIGUEGeneral disorders238/525232/521
DIARRHOEAGastrointestinal disorders236/525204/521
ALOPECIASkin and subcutaneous tissue disorders223/525226/521
NAUSEAGastrointestinal disorders170/525153/521
ANAEMIABlood and lymphatic system disorders154/52594/521
OEDEMA PERIPHERALGeneral disorders146/525134/521
CONSTIPATIONGastrointestinal disorders144/525124/521
PERIPHERAL SENSORY NEUROPATHYNervous system disorders99/525130/521
NEUTROPENIABlood and lymphatic system disorders125/52594/521
DECREASED APPETITEMetabolism and nutrition disorders125/525105/521

Baseline characteristics

Includes those from the Intent to Treat population (ITT). The ITT population is defined as all participants who were randomized, independent of whether they received study treatment or not.

Age, Continuous
Age, Continuous(years)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
Mean68.4 ± 7.7968.9 ± 7.9868.7 ± 7.89
Age, Customized
Age, Customized(Participants)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
<65 years171163334
> = to 65 years and < = 75years246244490
>75 years109126235
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
male5265331059
female000
Region of Enrollment
Region of Enrollment(Participants)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
US or Canada136140276
EU or Australia329330659
Rest of World (Includes 4 additional countries)6163124
Race, Customized
Race, Customized(Participants)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
White433436869
Other or no answer5567122
Black or African American252146
Asian8614
American Indian or Alaska Native538
Weight
Weight(kilograms)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
Mean86.4 ± 16.1886 ± 15.7086.2 ± 15.93
Height
Height(centimeters)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
Mean174.0 ± 7.81174.4 ± 7.38174.2 ± 7.60
Body Mass Index
Body Mass Index(kg/m^2)Docetaxel/Prednisone/Placebo (DP)Docetaxel/Prednisone/Lenalidomide (DPL)Total
Mean28.6 ± 5.0228.3 ± 4.6028.4 ± 4.81

8 further baseline measures are reported on the registry.

08

Study locations

210 sites
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Northern AZ Hematology and Oncology Assoc
    Sedona, Arizona 86336, United States
  • Arizona Oncology
    Tucson, Arizona 85710, United States
  • City of Hope Cancer Center
    Duarte, California 91010-3000, United States
  • Southwest Cancer Center - Escondido
    Escondido, California 92025, United States
  • Scripps Cancer Center - Clinical Research
    La Jolla, California 92037, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • The Angeles Clinc and Research Institute
    Los Angeles, California 90025, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Prostate Oncology Specialists
    Marina Del Rey, California 90292, United States
  • Stanford University Medical Center
    Stanford, California 94035-5821, United States
  • Rocky Mountain Cancer Centers-Colorado Springs Circle
    Colorado Springs, Colorado 80909, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Florida Cancer Institute - New Hope
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.- West Gore Street
    Orlando, Florida 32806, United States
  • South Florida Oncology - Hematology
    Tamarac, Florida 33321, United States
  • Palm Beach Cancer Institute, LLC
    West Palm Beach, Florida 33401, United States
  • Cancer Care and Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
  • Indiana University Health
    Indianapolis, Indiana 46219, United States
  • Hematology and Oncology Specialist, LLC
    Metairie, Louisiana 70006, United States
  • Maryland Oncology Hematology PA
    Columbia, Maryland 21044, United States
  • Minnesota Oncology Hematology, PA
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group Overlook Oncology Center
    Berkeley Heights, New Jersey 07922, United States
  • Hematology-Oncology Associates of NNJ, P
    Morristown, New Jersey 07960, United States
  • Hematology Oncology Associates of South Jersey
    Mount Holly, New Jersey 08060, United States
  • New York Oncology Hematology P.C.
    Albany, New York 12208, United States
  • Columbia Univ Medical Center
    New York, New York 10032, United States
  • Weill Cornell Medical College Dr. Feldman's Office
    New York, New York 10065, United States
  • New Bern Cancer Care
    New Bern, North Carolina 28562, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Mid Dakota Clinic, PC
    Bismarck, North Dakota 58501, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • Northwest Cancer Specialists-Tualatin
    Tualatin, Oregon 97062, United States
  • Ralph H. Johnson VA Medical Center
    Charleston, South Carolina 29401, United States
  • South Carolina Oncology Associates, PA
    Columbia, South Carolina 29210, United States
  • Cancer Center of the Carolinas
    Greer, South Carolina 29650, United States
  • Chattanooga Oncology Hematology Associates
    Chattanooga, Tennessee 37404, United States
  • Cookeville Regional Medical Center
    Cookeville, Tennessee 38501, United States
  • Sarah Cannon Research Institute UK
    Nashville, Tennessee 37203-1632, United States
  • Texas Oncology, P.A.-Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology-Arlington South
    Arlington, Texas 76014, United States
  • Texas Oncology, PA
    Austin, Texas 78758, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology, P.A.-Fort Worth
    Fort Worth, Texas 76104, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology, P.A. - Paris
    Paris, Texas 75460, United States
  • Southlake Oncology
    Southlake, Texas 76092, United States
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States
  • Texas Oncology Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Texas Oncology-Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Veterans Education and Research Association of Northern New England, Inc.
    White River Junction, Vermont 05009, United States
  • Cancer Outreach Associates
    Abingdon, Virginia 24211, United States
  • Fairfax Northern Virginia Hematology Oncology
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
  • Columbia Basin Hematology and Oncology
    Kennewick, Washington 99336, United States
  • VA Puget Sound HCS Seattle Division
    Seattle, Washington 98108-1532, United States
  • Evergreen Hematology and Oncology
    Spokane, Washington 99218, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia SA 5000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Flinders Medical Centre
    Bedford Park, 5042, Australia
  • Chris O'Brien Lifehouse
    Camperdown, NSW 2050, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, 6009, Australia
  • Port Macquarie Base Hospital
    Port Macquarie, NSW 2444, Australia
  • Redcliffe Hospital
    Redcliffe, QLD 4020, Australia
  • Royal North Shore Hospital
    St Leonards, 2065, Australia
  • Newcastle Calvary Mater Hospital
    Waratah, 2298, Australia
  • Westmead Hospital
    Westmead, NSW 2145, Australia
  • Border Medical Oncology
    Wodonga, 3690, Australia
  • The Queen Elizabeth Hospital
    Woodville South, 5011, Australia
  • Princess Alexandra Hospital
    Woolloongabba, QLD 4102, Australia
  • Medical University of Graz
    Graz, 8036, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Krankenhaus der Barmherzigen Brueder
    Vienna, 1020, Austria
  • Medizinische Universitat Wien
    Vienna, 1090, Austria
  • ZNA Middelheim
    Antwerpen, 2020, Belgium
  • Hopital Erasme
    Brussels, 1070, Belgium
  • Edith Cavell Clinic
    Bruxelles, 1180, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • AZ Nikolaas
    Sint-Niklaas, 9100, Belgium
  • The Health Institute for Men CMX Research Inc
    Toronto, Ontario M1P 2T7, Canada
  • Les Urologues Specialises
    Montreal, Quebec H2X 1N8, Canada
  • Krajska zdravotni, a.s. Nemocnice Chomutov, o.z.
    Chomutov, 430 12, Czechia
  • Fakultni nemocnice Motol
    Prague 5, 150 06, Czechia
  • Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad La
    Usti Nad Labem, 40113, Czechia
  • Arhus Universitets hospital
    Aarhus C, 8000, Denmark
  • Herlev Hospital
    Herlev, 2730, Denmark
  • Rigshospitalet University Hospital
    Kobenhavn, 2100, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • CRLCC Paul Papin
    Angers 49, 49933, France
  • Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
    Bordeaux, 33076, France

Showing the first 100 of 210 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2017 Feb;71(2):168-171. doi: 10.1016/j.eururo.2016.07.051. Epub 2016 Aug 10. PubMed 27522164 ↗
  • Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3. PubMed 25743937 ↗
  • de Morree ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA Oncol. 2017 Jan 1;3(1):68-75. doi: 10.1001/jamaoncol.2016.3000. PubMed 27560549 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Jan 2012, 26 months.

Results were first posted in Sep 2013, 1 year 7 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 26 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2009
First posted
Oct 2, 2009
StartActual
Nov 11, 2009
Primary completionActual
Jan 13, 2012
CompletionActual
Nov 28, 2016
Results first posted
Sep 5, 2013
Last update
Apr 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00988208
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 2, 2009
Start date
Nov 11, 2009
Primary completion
Jan 13, 2012
Completion
Nov 28, 2016
Results posted
Sep 5, 2013
Last update
Apr 4, 2018

Study contacts

Debora Barton, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion